Raynaud's Syndrome (Raynaud's Phenomenon): A Nutrition and Natural-Health Reference
Definition and Classification
Raynaud's phenomenon (RP) is a multifactorial vasospastic disorder characterized by a transient, recurrent, and reversible constriction of peripheral blood vessels. More specifically, it is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles, typically affecting the fingers and, less commonly, the toes, though it rarely also affects the nose, ears, nipples, or lips.
The current approach classifies RP into primary RP or idiopathic RP (also known as Raynaud's disease), and secondary RP (also known as Raynaud's syndrome). Secondary RP is often a clinical manifestation of an underlying disease. Conversely, if no underlying illness is detected, it is labeled as primary RP.
The condition is named after the physician Auguste Gabriel Maurice Raynaud, who first described it in his doctoral thesis in 1862. RP is documented to affect up to 5% of the general population, but variation in its prevalence is commonly recognized owing to many factors, including varied definitions, gender, genetics, hormones, and region.
Clinical Presentation
Patients with RP classically describe a triphasic discoloration of the affected area, beginning with pallor, followed by cyanosis, and finally ending with erythema. This change in color spares the thumb and is often associated with pain. Each attack may persist from several minutes to hours.
In people with Raynaud's phenomenon, blood vessels in the hands and feet react to cold or stress, narrowing quickly and staying constricted for a long period. This causes the skin to turn pale or white, then bluish as the blood left in the vessels becomes depleted of oxygen. Eventually, when the person warms up and the vessels expand again, the skin flushes and may tingle or burn.
The affected body parts are usually those most susceptible to cold injury β most often the fingers and toes, but also possibly the nose, earlobes, or nipples. Occasionally, even the tongue is involved.
Although relatively rare in primary Raynaud's phenomenon, ulcers may develop in the affected area due to lack of blood flow. The development of ulcers, scarring, and gangrene is more common in secondary Raynaud's phenomenon.
Body Systems Involved
The pathogenesis of RP involves an interplay of the vascular, intravascular, and neuronal factors (non-mutually exclusive) and cold- or stress-induced signaling pathways.
The Vascular System
Raynaud's syndrome is an exaggerated version of a normal body process called vasomotor response β meaning the blood vessels open up (vasodilation) and tighten (vasoconstriction) to help the body respond to its environment. For example, if it is cold outside, blood vessels near the skin's surface constrict to move blood to veins deeper in the body, conserving heat. Blood vessels also constrict when the person is stressed, to help the body save oxygen. Raynaud's disrupts this normal process, causing blood vessels to constrict more than they should, interrupting normal blood flow and limiting the oxygen available to fingers or toes.
Both structural and functional alterations observed in the blood vessels contribute to the vascular abnormalities documented in RP. However, functional impairment serves as a primary contributor to the pathophysiology of primary Raynaud's. Substances like endothelin-1, angiotensin, and angiopoietin-2 play a significant role in the vessel-mediated pathophysiology of RP. The role of nitric oxide in the development of this phenomenon is still complex.
The Nervous System
In all cases, the primary cause is an underlying hyperactivation of the sympathetic nervous system. Primary Raynaud's is characterized by heightened sensitivity of alpha-2 adrenergic receptors in digital and cutaneous vessels, causing vasoconstriction when exposed to cold and emotional stress. The distal arterial smooth muscles of the digits are affected by the sympathetic nervous system through receptors found in that area.
Neural abnormalities resulting in RP are recognized as being concerned with either central or peripheral mechanisms. CNS involvement in RP may be suggested by the fact that emotional distress and low temperature serve as major triggers for an attack, but recent observations have highlighted the importance of locally produced factors in this regard as well.
Digital cutaneous neurons show a deficient release of the vasodilatory calcitonin gene-related peptide in primary RP. This may represent a primary fault that is confounded by other factors which are influenced by cold or emotional triggers. Vasoconstricting substances such as catecholamines, endothelin-1, and 5-hydroxytryptamine, which may all be released in response to cold exposure, can cause digital artery closure and the associated symptoms of RP.
Intravascular and Immune Factors
In primary Raynaud's and systemic sclerosis, increased platelet activation and aggregation have been demonstrated. An increased production of platelet thromboxane A2, a potent vasoconstrictor, has been found in patients with Raynaud's phenomenon. Oxidative stress by reactive oxygen species has also been implicated in the pathogenesis of Raynaud's phenomenon.
In some cases, this cascade of neutrophil and platelet activation, through the release of inflammatory mediators, contributes to the endothelial damage seen with more severe RP.
Contributing and Associated Factors
Demographic and Genetic Factors
The pooled prevalence of primary RP in a systematic review and meta-analysis was 4.85% in the general population, with an annual incidence of 0.25%. Risk factors included female gender (OR=1.65), and family history (OR=16.6). Raynaud's phenomena occur more frequently in women (about 20β30%), particularly in younger age populations (teens to 20s), with a female-to-male ratio of 9 to 1.
More women than men are affected by primary Raynaud's phenomenon, suggesting that estrogen may play a role in this form. Genes may also be involved.
Associated Autoimmune and Connective Tissue Diseases
Although Raynaud's phenomenon has been described with various autoimmune diseases, the most common association is with progressive systemic sclerosis (90% in individuals with scleroderma) and mixed connective-tissue disease (85% prevalence). It is most commonly associated with connective tissue disorders such as scleroderma, systemic lupus erythematosus, SjΓΆgren syndrome, and antiphospholipid syndrome.
In secondary Raynaud's, the original disease disturbs typical blood vessel responsiveness, resulting in endothelial dysfunction and subsequent narrowing of blood vessels and tissue damage. For instance, systemic scleroderma leads to vascular fibrosis, causing endothelial dysfunction and ischemia.
Smoking and Nicotine
Female gender, positive family history, smoking, and migraines were found to be the major risk factors for primary RP in a systematic review of observational studies. Cessation of smoking is advised, as nicotine has been suggested to cause vasoconstriction.
Occupational Exposures
Raynaud's phenomenon is linked to occupational exposures such as vibration, cold temperature, and chemicals. Drugs such as antimigraine medications, interferon alpha and beta, cyclosporine, and nonselective beta blockers can cause secondary Raynaud's phenomenon. Occupations that result in overt vibrational exposure from vibrating machinery mostly affect males β this is known as hand-arm vibration syndrome. Exposure to polyvinyl chloride, cold injury from work, or ammunition work are other occupational-associated causes of secondary Raynaud's phenomenon.
Medications as Triggers
Risk factors for RP include certain medications (e.g., Ξ²-adrenoceptor blockers, clonidine), age, genetic history, cigarette smoking, alcohol consumption, anxiety, and stress. RP has also been observed to occur as a side effect of various drugs.
Infections and Other Conditions
Infections associated with secondary Raynaud's phenomenon include parvovirus B19, cytomegalovirus, hepatitis B, and hepatitis C. Other causes of secondary Raynaud's phenomenon include fibromyalgia, polycythemia, arteriovenous fistula, myalgic encephalitis, or malignancy.
Vascular smooth muscle hypertrophy is implicated in conditions such as hand-arm vibration syndrome; increased blood viscosity in hematologic conditions and impaired erythrocyte flexibility may induce manifestations of RP. Increased sympathetic tone with neurotransmitter release or peripheral nerve compressions in conditions such as thoracic outlet or carpal tunnel syndrome also contributes to RP pathogenesis.
Nutrients, Herbs, and Natural Ingredients
This section separates traditional use from scientific evidence for each substance reviewed in the peer-reviewed or institutional literature. Adjunctive dietary supplements, including omega-3 fatty acids, Ginkgo biloba, and antioxidant vitamins, show biological plausibility but lack high-quality clinical evidence. Across all treatment modalities, high-quality randomized controlled trials remain limited, and standardized outcome measures are inconsistently applied.
Omega-3 Fatty Acids (Fish Oil / EPA and DHA)
Biological Rationale
The ingestion of omega-3 fatty acids could benefit patients with Raynaud's phenomenon because, among other effects, these fatty acids induce a favorable vascular response to ischemia. There is some evidence that a diet rich in omega-3 fatty acids may be beneficial in preventing Raynaud's phenomenon.
Scientific Evidence
A double-blind, placebo-controlled study investigated the effects of fish-oil fatty-acid dietary therapy in patients with rheumatic disease. Thirty-two patients with primary or secondary Raynaud's phenomenon were randomly assigned to an olive-oil placebo or fish-oil group. Patients ingested 12 fish-oil capsules daily containing a total of 3.96 g eicosapentaenoic acid (EPA) and 2.64 g docosahexaenoic acid (DHA), and were evaluated at baseline and after six, twelve, and seventeen weeks.
In the fish-oil group, the median time interval before the onset of Raynaud's phenomenon increased from 31.3 Β± 1.3 minutes at baseline to 46.5 Β± 2.1 minutes at six weeks (p = 0.04). The authors concluded that the ingestion of fish oil improves tolerance to cold exposure and delays the onset of vasospasm in patients with primary, but not secondary, Raynaud's phenomenon. These improvements were associated with significantly increased digital systolic blood pressures in cold temperatures.
Evidence strength: Systematic reviews and clinical guidelines generally consider the evidence as limited and insufficient to recommend omega-3 supplementation as a standard therapy for Raynaud's disease. The existing evidence base is not robust due to methodological limitations and inconsistent findings. While there is some scientific rationale and preliminary evidence supporting the use of omega-3s for Raynaud's, the overall quality and quantity of evidence are low.
Evening Primrose Oil (Gamma-Linolenic Acid / GLA)
Biological Rationale
Prostaglandin E1 (PGE1) and prostacyclin have been used in Raynaud's phenomenon but are unstable and require intravenous administration. An alternative approach is to stimulate the body's own PGE1 production via administration of the precursor essential fatty acid. Gamma-linolenic acid (GLA), a healthy omega-6 fatty acid found in evening primrose oil and borage oil, has blood-thinning effects that may help relieve symptoms of Raynaud's phenomenon.
Scientific Evidence
A study examined the effect of 12 capsules per day of evening primrose oil (EPO) on the manifestations of RP. Twenty-one patients received a two-week course of placebo; thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened, the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects. The authors concluded that patients receiving EPO benefited symptomatically.
Evidence strength: This is a single small placebo-controlled trial (n=21) with subjective primary outcomes and no objective plethysmographic benefit. The evidence is preliminary and requires replication in larger trials.
Ginkgo biloba
Traditional Use
Ginkgo biloba leaf extracts have been used in traditional Chinese medicine for millennia, primarily to address circulatory and cognitive concerns. In Western herbal practice, standardized leaf extracts (standardized to ginkgo flavone glycosides and terpene lactones) became popular in the late twentieth century for peripheral vascular insufficiency and intermittent claudication. Its use in Raynaud's is an extension of this peripheral-circulation application and is not rooted in ancient-specific ethnobotanical texts for the condition itself.
Scientific Evidence
A double-blind, placebo-controlled trial investigated the clinical efficacy of a standardized Ginkgo biloba extract (Seredrin) in the treatment of RP in patients with no apparent associated condition such as systemic sclerosis. A two-week assessment period was done during which patients recorded frequency, severity, and duration of attacks in diaries. Subjects were then randomized to receive either active or placebo treatment for 10 weeks, during which time the same data were recorded. Patients were seen after two and four weeks of treatment and at the end of the 10-week treatment phase.
The number of attacks per week prior to treatment with Seredrin was 13.2 Β± 16.5, reducing to 5.8 Β± 8.3 β a reduction of 56% β whereas placebo reduced the number by only 27% (p β€ 0.00001). There were no significant differences in haemorheology between the two groups.
However, a later placebo-controlled trial using the EGb 761 extract showed an excellent safety profile in patients with Raynaud's disease but could not demonstrate a statistically significant reduction in clinically relevant symptoms compared with placebo.
Evidence strength: Historical results for the treatment of Raynaud's with Ginkgo biloba show some promise, but to date the improvements have been found insignificant in some clinical trials. The totality of evidence is therefore mixed: one small trial showed significant attack frequency reduction, while at least one other failed to confirm the effect. Evidence is rated as preliminary to weak.
L-Arginine
Biological Rationale
The amino acid L-arginine is important for the synthesis of nitric oxide, a potent vasodilator. Nitric oxide metabolism and signalling plays an important and diverse role in the pathophysiology of secondary Raynaud's phenomenon. Failure of flux through endothelial nitric oxide synthase (eNOS) contributes to increased vasoconstriction and decreased vasorelaxation. The underproduction of nitric oxide by eNOS is in part due to increased levels of asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase.
Scientific Evidence
It has been hypothesized that nitric oxide may have a role in Raynaud's phenomenon. Two cases have been reported in which oral L-arginine reversed digital necrosis in Raynaud's phenomenon, and two additional cases in which the symptoms of severe Raynaud's phenomenon were improved with oral L-arginine. These reports suggest that a defect in nitric oxide synthesis or metabolism is present in Raynaud's phenomenon and suggest a potential role for oral L-arginine therapy, especially in Raynaud's phenomenon with digital necrosis.
The inhibitory effects of increased ADMA levels may be counteracted by increasing serum L-arginine, which is often an effective treatment strategy in these patients. L-arginine-based therapies should be considered in managing secondary RP, particularly given their favourable safety and tolerability profile.
Evidence strength: The direct clinical evidence for oral L-arginine in Raynaud's consists of case reports only (n=4). The mechanistic rationale via nitric oxide/ADMA is well-characterized in peer-reviewed literature, but large-scale controlled human trials in RP populations have not been published. Evidence is currently preliminary.
Inositol Hexanicotinate (Flush-Free Niacin / Hexopal)
Biological Rationale
Inositol hexanicotinate is an ester of niacin (vitamin B3) and inositol. Niacin, in pharmacological doses, is a known peripheral vasodilator. Its application to Raynaud's rests on this vasodilatory property and on the observation that peripheral circulation to the extremities may be improved.
Scientific Evidence
The peripheral vasospastic symptoms associated with Raynaud's disease continue to be an unsolved clinical problem. Hexopal (inositol hexanicotinate) has shown promise in uncontrolled studies, and its use in patients with Raynaud's disease may reduce vasospasm. One study examined the effects of 4 g/day of Hexopal or placebo during cold weather in 23 patients with primary Raynaud's disease. The Hexopal group felt subjectively better and had demonstrably shorter and fewer attacks of vasospasm during the trial period. Serum biochemistry and rheology were not significantly different between the two groups. Although the mechanism of action remains unclear, Hexopal was described as safe and effective in reducing vasospasm of primary Raynaud's disease during winter months.
Evidence strength: Evidence to date has not proven vitamin B3 (niacin) effective in clinical trials for Raynaud's, and there are several potential side effects that should be carefully considered. The inositol hexanicotinate data consists of a single small trial and uncontrolled studies. The evidence is weak.
Magnesium
Biological Rationale
One study found that decreased serum magnesium levels were more common in women with primary Raynaud's than in healthy women. Magnesium is required to maintain smooth muscle relaxation in blood vessels. Additionally, the requirement for magnesium increases with physical and emotional stress, both known to trigger Raynaud's phenomenon. Furthermore, low magnesium levels can increase endothelial contractility when magnesium requirements are not met, potentially impacting Raynaud's.
A noted alternative medical specialist has described magnesium as potentially working like a "natural calcium channel blocker" β the class of drugs clinically proven to relieve symptoms in Raynaud's patients.
Scientific Evidence
Evidence strength: Magnesium has not been sanctioned by the medical community as a viable treatment for Raynaud's. As of available peer-reviewed literature, no large-scale randomized controlled trials specifically examining magnesium supplementation in Raynaud's populations have been identified. The evidence is mechanistically plausible but clinically unproven.
Vitamin E (Tocopherol)
Biological Rationale
Vitamin E is a lipid-soluble antioxidant capable of reducing oxidative stress and improving microvascular function. Given that oxidative stress by reactive oxygen species has been implicated in the pathogenesis of Raynaud's phenomenon, antioxidant nutrients have attracted investigational interest.
Scientific Evidence
One study on individuals experiencing Raynaud's as a consequence of working with vibrating machinery found that supplementation with 600 mg of alpha-tocopherol nicotinate daily for 6 weeks improved subjective symptoms such as numbness and cold sensation; clinical examinations also indicated improvement.
Evidence strength: The available vitamin E data in Raynaud's is restricted to a single occupational cohort study involving a specific tocopherol ester (alpha-tocopherol nicotinate), limiting generalizability. Evidence is preliminary and insufficient to draw broader conclusions.
Ginger (Zingiber officinale)
Traditional Use
Ginger rhizome has a long history of use in Ayurvedic, Chinese, and European traditional medicine as a warming circulatory stimulant. It has been used to improve peripheral circulation, address cold extremities, and reduce vascular stagnation. Preparations include fresh or dried rhizome decoctions, tinctures, and standardized extracts. Its use for Raynaud's specifically is an extension of this circulatory-warming tradition rather than a documented ethnobotanical indication.
Scientific Evidence
No clinical trials specifically examining ginger supplementation in Raynaud's populations have been identified in the peer-reviewed literature. The biological rationale rests on gingerols and shogaols' known effects on thromboxane synthesis inhibition and vasodilation in preclinical models, but human evidence in the context of RP is absent. Evidence is preclinical only.
Dietary and Lifestyle Factors
Cold Avoidance and Body Warming
Raynaud's phenomenon attacks affect certain parts of the body, especially the fingers and toes, causing them to become cold and numb and change colors. Exposure to cold temperatures is the most common trigger, such as grabbing hold of a glass of ice water or taking something out of the freezer. Sudden changes in ambient temperature, such as when entering an air-conditioned supermarket on a warm day, can also lead to an attack. Emotional stress, cigarette smoking, and vaping can also trigger symptoms.
Patient education regarding lifestyle modifications is the cornerstone of managing both primary and secondary RP. This includes advice on avoiding cold exposure; warming the entire body, not just hands and feet, by dressing in layers and covering the head; smoking cessation; stress and anxiety management; avoiding medications with vasoconstrictive effects; and avoiding microtrauma from excessive vibrations.
Smoking Cessation
Anxiety management, measures to avoid colder temperatures, and smoking cessation, along with other simple modifications, have proven to be effective non-drug strategies in patients experiencing milder symptoms. Smoking is considered a significant modifiable risk factor: smoking was associated with a significantly increased odds ratio (OR=1.27) for primary RP in the systematic review meta-analysis.
Caffeine Avoidance
Avoiding caffeine is recommended as a lifestyle consideration, as caffeine is a vasoconstrictor. Avoiding caffeine is listed among self-care measures for managing Raynaud's syndrome. The evidence base for this recommendation is largely physiological and observational rather than derived from dedicated intervention trials in RP populations.
Vibration Avoidance
Avoiding touching anything that vibrates is an important lifestyle consideration for those with Raynaud's phenomenon. This recommendation is grounded in the well-established occupational evidence linking hand-arm vibration to secondary RP. Non-pharmacologic measures, including trigger avoidance, temperature management, smoking cessation, and patient education, remain foundational, particularly for primary RP.
Emotional Stress Management
Stress is a well-known trigger for Raynaud's episodes. The connection between stress and Raynaud's lies in the body's "fight or flight" response or sympathetic nervous system. When stressed, the body releases hormones like adrenaline, which can cause blood vessels to narrow. In someone with Raynaud's, this response may exacerbate vasospasms, leading to more pronounced symptoms.
Alleviation of emotional stress and anxiety can also decrease the frequency of the onset of these attacks.
Diet and Omega-3-Rich Foods
A dietary consult is recommended as there is some evidence that a diet rich in omega-3 fatty acids may be beneficial in preventing Raynaud's phenomenon. This is consistent with the clinical trial evidence reviewed above, where fish oil supplementation benefited primarily primary RP. Foods rich in EPA and DHA β including oily fish such as salmon, mackerel, sardines, and herring β represent a dietary avenue aligned with this evidence, though no dietary intervention trials have been conducted separately from supplement trials.
Overall Evidence Context
The general assessment from specialist bodies is that there is a lack of scientific support for the use of natural remedies in the treatment of Raynaud's phenomenon. While some Raynaud's sufferers may have had a positive experience trying certain vitamins, holistic treatments or other measures, to date there is no robust clinical evidence that any of these options will reliably improve Raynaud's symptoms. Lifestyle modifications β particularly cold avoidance, smoking cessation, and stress reduction β remain the best-supported non-pharmacological strategies.
References
- Nawaz I et al. "Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies." PMC / Cureus, 2022.
- Musa R, Qurie A. "Raynaud Disease." StatPearls. NCBI Bookshelf, 2023.
- Garner R et al. "Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis." PMC / BMJ Open, 2015.
- Vsijournal.org. "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment." PMC, 2024.
- DiGiacomo RA et al. "Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study." American Journal of Medicine, 1989. PMID: 2536517.
- Belch JJ et al. "Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study." Thrombosis and Haemostasis, 1985. PMID: 4082084.
- Muir AH et al. "The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial." Vascular Medicine, 2002. PMID: 12710841.
- Rembold CM, Ayers CR. "The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon." PMC / British Journal of Clinical Pharmacology, 2019.
- Rembold CM, Ayers CR. "Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon." Molecular and Cellular Biochemistry, 2003. PMID: 12701823.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). "Raynaud's Phenomenon: Symptoms, Types, & Risk Factors." NIH, updated 2025.
- Yeo RE et al. "Risk of Raynaud's Phenomenon Among Workers in the Occupational Disease Surveillance System." American Journal of Industrial Medicine, 2025.
- Herrick AL. "The aetiology of Raynaud's phenomenon." Cardiovascular Research, 1998. PMID: 9794259.
- PMC. "Primary Raynaud's Phenomenon of the Tongue." PMC, 2024.
- Quality in Sport. "Modern Approaches to Raynaud's Phenomenon: Pathophysiology, Treatment, and Emerging Therapies." 2026.
- Raynaud's Association. "Natural Remedies for Raynaud's Lack Scientific Support." 2018.
- Wikipedia. "Raynaud Syndrome." (for historical and terminological background only).
Go back